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Application of real-time PCR and melting 
curve analysis in rapid Diego blood group 
genotyping
M.C.Z. Novaretti, A.S. Ruiz, P.E. Dorlhiac-Llacer and D.A.F Chamone
The paucity of appropriate reagents for serologic typing of the 
Diego blood group antigens has prompted the development of a 
real-time PCR and melting curve analysis for Diego blood group 
genotyping. In this study, we phenotyped 4326 donor blood 
samples for Dia using semiautomated equipment. All 157 Di(a+) 
samples were then genotyped by PCR using sequence-specific 
primers (PCR-SSP) for DI*02 because of anti-Dib scarcity. Of 
the 4326 samples, we simultaneously tested 160 samples for Dia 
and Dib by serology, and for DI*01 and DI*02 by PCR-SSP and 
by real-time PCR. We used the same primers for Diego geno-
typing by real-time PCR and PCR-SSP. Melting curve profiles 
obtained using the dissociation software of the real-time PCR 
apparatus enabled the discrimination of Diego alleles. Of the 
total samples tested, 4169 blood donors, 96.4 percent (95% 
confidence interval [CI], 95.8–96.9%), were homozygous for 
DI*02 and 157, 3.6 percent (95% CI, 3.1–4.2%), were heterozy-
gous DI*01/02. No blood donor was found to be homozygous 
for DI*01 in this study. The calculated DI*01 and DI*02 allele 
frequencies were 0.0181 (95% CI, 0.0173–0.0189) and 0.9819 
(95% CI, 0.9791–0.9847), respectively, showing a good fit for 
the Hardy-Weinberg equilibrium. There was full concordance 
among Diego phenotype results and Diego genotype results by 
PCR-SSP and real-time PCR. DI*01 and DI*02 allele determina-
tion with SYBR Green I and thermal cycler technology are useful 
methods for Diego determination. The real-time PCR with SYBR 
Green I melting temperature protocol can be used as a rapid 
screening tool for DI*01 and DI*02 blood group genotyping. 
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The Diego blood group system was named after iden-tifying a new antibody, anti-Dia, which caused HDN resulting in the death of a Venezuelan newborn in 
1955.1,2 Anti-Dib was described in 1967 in two Mexicans by 
Thompson et al.3 Anti-Dia and -Dib are  clinically relevant. 
Both have been implicated in transfusion reactions and in 
HDN.4–6
 The Diego blood group system comprises 21 antigens, 
and Dia and Dib are the most clinically signifi cant.7 Although 
Dib is present in virtually all populations, Dia incidence var-
ies substantially worldwide. It is found in 7 to 54 percent of 
South American Indians, 5 to 8 percent of Asians (Chinese, 
Korean, Japanese), and 14.7 percent of Mexican Americans, 
whereas it is rare in Whites and Blacks (0.01%).3,8,9
 Dia and Dib are carried on band 3 protein. The single 
SLC4A1 gene (solute carrier family 4, anion exchanger, 
member 1) controls band 3 expression. This gene extends 
on an 18-kilobase (kb) genomic DNA, maps to chromo-
some 17q12–q21, and consists of 20 exons.10 The DI*01 and 
DI*02 alleles code for the antithetical Dia and Dib antigens, 
respectively.11
DI*01 and DI*02 polymorphism is determined by a 
T>C nucleotide substitution at position +2561 in exon 19 
of the SLC4A1 gene, changing the leucine at amino acid po-
sition 854 to a proline in the band 3 protein.12 No healthy 
individual with a Diego null phenotype has been reported, 
refl ecting the functional importance of band 3. Although no 
Di(a–b–) subjects have been recognized by serologic test-
ing, Alloisio et al.13 described one individual who is homozy-
gous for a band 3 mutation, Va1488Met (band 3 Coimbra), 
that results in almost complete defi ciency of band 3. At the 
clinical level, Diego blood group antigens are of consider-
able importance in relation to their role in transfusion reac-
tions and HDN. The Brazilian population is composed of a 
highly mixed ancestry, with an incidence of 1.3 percent of 
Di(a+) blood donors.14 Consequently, multiply transfused 
individuals can have anti-Dia or rarely anti-Dib.14–16 Further-
more, commercial anti-Dia for serologic testing is scarce, 
and there is no available commercial anti-Dib for routine 
use. The aim of this study was therefore to describe a DNA-
based typing method that allows blood samples to be tested 
for DI*01 and DI*02 using a PCR real-time method.
Material and Methods
 This is a prospective study performed at Fundação 
Pró-Sangue/Hemocentro, São Paulo, Brazil. A total of 
4326 venous blood samples from unrelated Brazilian vol-
unteer blood donors were collected in EDTA and tested for 
Dia by hemagglutination. Every Di(a+) blood sample was 
then tested for Dib by PCR using sequence-specifi c primers 
(PCR-SSP) owing to anti-Dib scarcity. We then performed 
real-time PCR validation for Diego genotyping. Finally, we 
performed Diego analysis in 160 of 4326 blood samples for 
Dia and Dib by serologic studies, PCR-SSP, and real-time 
PCR simultaneously. The results were interpreted blinded 
from the serologic results.
 Dia phenotyping was performed using 50 μL of anti-Dia
(DiaMed AG, Cressier-sur-Morat, Switzerland) and 25 μL 
of a 1% RBC suspension dispensed into a microplate using 
semiautomated equipment (Megafl ex-TECAN, TECAN AG, 
Hombrechtikon, Switzerland). After incubation for 30 min-
utes at 37°C, the microplates were centrifuged at 468g for 
15 seconds. The microplates were then washed three times 
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with saline solution and centrifuged at 468g for 15 seconds. 
Fifty μL of antihuman globulin (AHG) serum (DiaMed La-
tino America, Lagoa Santa, Brazil) was added to each well; 
the microplates were centrifuged at 468g for 15 seconds, 
and read immediately. Dib phenotyping was performed 
in gel cards (DiaMed Latino America) using anti-Dib pre-
viously identified in a patient. The donor’s RBCs were 
washed three times in 0.9% saline solution and suspended 
in LISS (ID-Diluent 2, DiaMed Latino America) to a final 
0.8% suspension. In a microtube of the LISS/AHG ID card 
(DiaMed Latino America), 50 µL of 0.8% donor RBCs and 
25 µL of patient’s serum were dispensed and incubated 
at 37°C for 15 minutes in an appropriate incubator (ID- 
Incubator 37SI, DiaMed AG). After incubation, the cards 
were centrifuged for 10 minutes in an appropriate centri-
fuge (ID-Centrifuge 24S, DiaMed AG). After centrifuga-
tion, the cards were examined for agglutination or hemo-
lysis according to the manufacturer’s instructions. Positive 
and negative known control samples were included in each 
batch for Diego phenotyping validation results.
DNA Extraction
 Human genomic DNA was isolated from whole blood in 
duplicate, using a commercial DNA extraction kit (QIAamp 
DNA Blood Mini Kit, QIAGEN Science, Hilden, Germany). 
DNA was extracted from 200 μL of blood and eluted in 100 
μL of buffer according to the manufacturer’s recommenda-
tions. For all samples, a mean of 100 ng of DNA was ob-
tained. DNA was stored at –20°C for long-term storage.
PCR-SSP
 All samples were genotyped in duplicate for DI*01 
and DI*02 alleles by the PCR-SSP method and real-time 
PCR simultaneously, using primers designed by Wu et al.17 
(Table 1) The F2/AR pair of primers detected the DI*01 
allele, and the BF/R pair detected DI*02. Primers ampli-
fying a fragment of the human growth hormone (HGH) 
gene served as an internal control.18,19 PCR-SSP was car-
ried out in a final volume of 25 μL containing 100 ng of 
purified DNA, 1.5 μL of MgCl2 (1.5 mM), 1 μL of dNTP mix 
(0.2 mM, Invitrogen, Carlsbad, CA), 1.5 U of Taq 
polymerase (Platinum Taq DNA Polymerase, In-
vitrogen, São Paulo, Brazil), 2.5 μL of Tris-HCl 
(10 mM, pH 8.3, 50 mM KCl), 0.3 μM of each 
forward and reverse primer, and 0.08 μM of in-
ternal control. Amplifications were programmed 
on the thermocycler (Mastercycler gradient, Ep-
pendorf AG, Hamburg, Germany), at the follow-
ing conditions: denaturation at 95°C for 5 min-
utes, then 30 cycles of 30 seconds at 95°C, 30 
seconds at 60°C, and 90 seconds at 72°C.17 The 
reactions were completed by an elongation step 
for 5 minutes at 72°C. PCR products were visu-
alized in a 2% agarose gel stained with ethidium 
bromide under 100 V using photodocumentation 
equipment (Eagle-eye; Stratagene, La Jolla, CA). 
Real-time PCR 
 The same two sets of primers used for DI*01 and DI*02 
polymorphism detection by PCR-SSP were also used for 
real-time PCR. Real-time PCR was carried out in 0.1-mL 
strip tubes and Caps (Corbett Research, Mortlake, Austra-
lia) using the same primers used for the PCR-SSP method 
(Table 1). Each reaction contained 7.5 μL of 2x Quantitect 
SYBR Green PCR Master Mix (QIAGEN Science), 0.3 μM of 
each forward and reverse primer, 100 ng of genomic DNA, 
and nuclease-free water in a final volume of 15 μL. PCR 
amplifications and fluorescence detection were performed 
using Rotor Gene 3000 equipment (Corbett Research, Syd-
ney, Australia). The PCR amplification profile was a 95°C 
enzyme activation step (10 minutes), followed by 35 cycles 
of 95°C denaturation (30 seconds), 60°C annealing (30 sec-
onds), and 72°C extension (90 seconds). Melting curves were 
generated by monitoring the continuous decrease in fluores-
cence of the SYBR Green signal from 75° to 95°C at the end 
of each run. Data acquisition and analysis were handled by 
the Rotor Gene 6 software (Corbett Research). In each run, 
we included samples homozygous for DI*01 and DI*02 used 
in the validation process as control samples.
Statistical Analysis
 Allele frequencies were calculated by direct gene count-
ing, and the differences were analyzed by the χ2 test using 
a 2 × 2 contingency table. All analyses were performed on 
Statistica software (SAS Institute, Cary, NC).
Results
Real-time PCR Validation
 In the validation process of real-time PCR for DI*01 and 
DI*02, we tested 62 reference samples from the Fundação 
Pró-Sangue, after which these samples were genotyped for 
DI*01 and DI*02 using PCR-SSP (Figure 1A) and by real-
time PCR (Figure 1B) on two occasions. The results were 
interpreted blinded from the serologic results. We found a 
genotype-specific melting profile for DI*01 and DI*02, with 
both amplifications performed in one single run. This step 
was critical for the optimization of our real-time PCR protocol 
Table 1. Primers used for DI genotyping by PCR SSP and real-time PCR









F2† GTGCTGGGGTGTGATAGGC (17) F2/AR DI*01  139
AR† CAGGGCCAGGGAGGCCA
BF† GGTGGTGAAGTCCACGCC (17) BF/R DI*02 129
R† CCAGGCAGCCACTCACAC




†GenBank accession no. AC003043 for SLC4A1
F = indicates forward primer; R = reverse primer.
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and for determination of the Tm (melting temperature at 
which double-strand DNA is broken down to single-strand 
DNA) for DI*01 (86.94°C) and DI*02 (88.04°C) (Figure 2). 
Of 62 samples tested, 49 were found to be homozygous for 
DI*02. Eleven were DI*01/02, and two were DI*01/01. Our 
results for DI*01 and DI*02 genotyping with real-time PCR 
were totally concordant with those obtained by PCR-SSP. 
The two samples with a DI*01/01 genotype by PCR-SSP al-
lowed us to establish and validate the detection of the DI*01 
homozygous allele by real-time PCR.
Comparison of Phenotyping with Hemagglutination, 
PCR-SSP, and Real-time PCR for DI*01 and DI*02
 The sensitivity of our real-time PCR assay was verifi ed 
by correctly identifying 160 samples for DI*01 and DI*02
by serology, PCR-SSP, and real-time PCR. Of these, 127 
were found to be DI*02/02 and 33 were DI*01/02. No 
single DI*01/01 sample was identifi ed in this series. All ho-
mozygous and heterozygous alleles have been distinguished 
by melting curve analyses. Although no DI*01 homozygous 
individual was found in this series, we tested two DI*01/01
samples in the validation step, and both were also identi-
fi ed by real-time PCR. Our results of Diego genotyping us-
ing real-time PCR were consistent and totally concordant 
with those results obtained using PCR-SSP. No discrepant 
results were observed among the three methodologies eval-
uated in our study.
Analysis of Diego Genotype and Allele Frequencies 
in Brazilian Blood Donors
 Phenotype frequencies were estimated in Brazilian 
blood donors (Table 2). Among 4326 blood donors tested, 
4169 (96.4%; 95% confi dence interval [CI], 95.8–96.9%) 
were homozygous for DI*02 and 157 (3.6%; 95% CI, 3.1–
4.2%) were DI*01/02 heterozygous. No blood donor was 
found to be homozygous for DI*01 in this study (Table 2). 
We assumed that no blood donor presented the very rare 
band 3–defi cient phenotype for Diego genotype and allele 
frequency calculation. The calculated DI*01 and DI*02 al-
lele frequencies were 0.0181 (95% CI, 0.0173–0.0189) and 
0.9819 (95% CI, 0.9791–0.9847), respectively, showing a 
good fi t for the Hardy-Weinberg equilibrium (Table 3).
Discussion
 In the last 10 years, the vigorous globalization process 
has made international travel and signifi cant immigration 
extraordinarily common. Rare blood can be necessary in 
unexpected regions, causing an extra impact on blood ser-
vices. Consequently, the Diego blood group system is of 
Table 3. Allele frequencies of DI*01 and DI*02 in 4326 Brazilian 
blood donors
Diego alleles Allele frequency 95% CI
DI*01 0.0181 0.0173–0.0189
DI*02 0.9819 0.9791–0.9847
CI = confi dence interval.
Fig. 1. PCR-SSP typing for DI*01 and DI*02 alleles. A 434-bp 
fragment of HGH was amplifi ed as an internal control. Lane M 
shows a 100-bp ladder. (A) DI*01 was determined by the presence 
of 139-bp fragment. From left to right: Blank (lane 1), DI*01-positive 
samples (lanes 2, 3), DI*01-negative (lanes 4, 5), DI*01-positive 
control (lane 6). (B) DI*02 allele was determined by the presence 
of specifi c PCR product (129-bp).From left to right: DI*02-positive 
control (lane 1), Blank (lane 2), DI*02-positive samples (lanes 3, 4, 
5, 6, 7, 8, 9) and negative control for DI*02 (10).
Fig. 2. Melting curve analysis of samples genotyped as (A) 
DI*01/01, (B) DI*02/02,and (C) DI*01/02. The DI*01 and DI*02 Tm 
were determined at 86.94° and 88.04°C, respectively.The arrows 
indicate controls (positive, negative) for DI*01 and DI*02, blank, and 
sample donors tested.
Table 2. Diego phenotype incidence in 4326 Brazilian blood donors
Phenotype Number % 95% CI
Di(a–b+) 4169 96.4 95.8–96.9
Di(a+b+) 157 3.6 3.1–4.2
Di(a+b–) 0 0 —
Total 4326 100
χ2 = 1.4776.
CI = confi dence interval.
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clinical importance not only in Latin America but also in 
many other countries. Different approaches can be taken to 
deal with this situation.
 Diego phenotyping has not been routinely performed 
in several blood services owing to the scarcity of commer-
cial anti-Dia. The situation is critical for Dib, as there is no 
available commercial anti-Dib. Therefore, whenever there is 
a suspicion of anti-Dia or -Dib, two problems are faced: one 
is to confirm the antibody specificity against the Diego anti-
gens with appropriate controls (negative and positive), and 
the other is to find units negative for the antigen involved.
 This need led us to search for an alternative approach 
for Diego blood group antigen testing and for the selection 
of blood units negative for Dia or Dib. Diego genotyping can 
be performed using the PCR-SSP method. However, PCR-
SSP is a time-consuming assay as it requires post-PCR han-
dling, and it has been shown to be inadequate for large-scale 
implementation.20
 Wu et al.17 described a PCR-SSP method for DI*01 and 
DI*02 genotyping that we used in this study. They tested 
different primer combinations and tried to use a single tube 
for PCR-SSP technique to identify DI*01 and DI*02 alleles 
in the same reaction. However, the results were disappoint-
ing, and they had to use two tubes, generating two separate 
products. Consequently, we used two separate protocols to 
test for DI*01 and DI*02 by PCR-SSP.
 Real-time PCR for DI*01 and DI*02 allele determina-
tion can overcome these drawbacks because it allows spe-
cific amplification without post-PCR manipulations. More-
over, real-time PCR decreases the risk of error by the simple 
fact that it reduces the number of manual steps.21 Recently, 
Polin et al.22 also described the methodology for real-time 
PCR as an effective tool for blood group genotyping.
 As labeled probes are costly when compared to real-
time PCR with SYBR Green I, we decided to use the latter 
for cost reduction.23 This decision also optimized our strat-
egy for DNA analysis of other blood group systems, as we 
saw no need to purchase special primers.
 The real-time PCR protocol that we developed allowed 
us to use the same primers we had been using for PCR-SSP 
in a universal cycling program, performing the same proto-
col to identify DI*01 and DI*02 alleles. The advantages of 
this real-time PCR method are the rapid performance and 
the detection of two alleles in the same run. The PCR assay 
revealed 100 percent specificity as assessed by comparison 
of genotype data to those generated by serologic typing. The 
Diego genotyping method described here, based on SYBR 
Green I by real-time PCR, can be used as a high-throughput 
discrimination of the DI*01 and DI*02 alleles (Figure 2). 
This approach takes advantage of the fluorescent proper-
ty of SYBR Green I and of the melting curve analysis for 
the detection and discrimination of amplicons differing in 
length and nucleotide content.
 One limitation of this study is that we were not able to 
detect the rare band 3 mutation called Coimbra, because 
we had not tested all samples by the three methods chosen. 
However, it would be highly unlikely to find one, as to date 
band 3 Coimbra mutation has been associated with ane-
mia, and we only included nonanemic individuals (blood 
donors) in our study.13
 Finally, we analyzed DI*01 and DI*02 genotype and 
allele frequencies in 4326 Brazilian blood donors. There 
are significant differences of DI*01 and DI*02 allele ex-
pression among world populations. The DI*01 allele is 
considered rare in Whites,24,25 but is characteristic in 
some Asians and in South American Indians with a gene 
frequency as high as 40 percent.1,4  We detected Dia in 3.6 
percent of blood donors, with a DI*01 gene frequency of 
0.0181, indicating the complex ancestry miscegenation of 
the Brazilian population. This study was conducted in São 
Paulo State, located in southern Brazil, which is character-
ized by lower levels of African and higher degrees of Eu-
ropean contributions when compared with other Brazilian 
groups.26 Moreover, our results can be explained in part 
by the successive migratory waves from 1500 to the 20th 
century that contributed to the formation of the multi- 
ethnic highly admixed Brazilian population. This hetero-
geneity was documented in several genetic studies, which 
demonstrated a typical although nonuniform triethnic (Eu-
ropean, African, and Amerindian) population gene pool.27
 In conclusion, we developed a real-time PCR protocol 
for DI*01 and DI*02 genotyping that is feasible and easy 
to perform on a high-throughput scale. It can improve and 
facilitate anthropologic and epidemiologic studies on DI*01 
and DI*02 allele determination.
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